At present, postoperative adjuvant chemotherapy and radiotherapy are still the main treatment methods for patients with stage III or below radical resection of rectal cancer with gene mutation. However, for some patients with stage IV rectal cancer gene mutation, anti-angiogenic drugs, mainly bevacizumab, are still the mainstay in clinical practice, and the use of monoclonal antibodies together with adjuvant radiotherapy and chemotherapy is needed to achieve the best therapeutic effect and maximize the survival of patients. Immunotherapy is currently in the process of research, and although the research has not yet been groundbreaking, the results will become better and better with attempts at multi-targeted combination therapy.